Purpose Biochemical control is the main determinant of survival, clinical manifestations and
comorbidities in acromegaly. Transsphenoidal selective adenomectomy (TSA) is the initial …

Objective Data on sex differences in acromegaly at the time of diagnosis vary considerably
between studies. Design A nationwide cohort study including all incident cases of …

Abstract Purpose The Pituitary Society established the concept and mostly qualitative
parameters for defining uniform criteria for Pituitary Tumor Centers of Excellence (PTCOEs) …

Context Transsphenoidal surgery (TSS) is the primary treatment of choice in acromegaly. It
is important to identify patients in whom surgical cure is not attainable at an early stage, both …

Objective To study time‐related changes in the prevalence and patient characteristics of
acromegaly, as well as to assess the impact of changes in treatment on disease control …

This review aimed to highlight the history, diagnostic criteria, preoperative prognostic factors,
surgical management, and multimodal adjuvant therapies recommended to provide a …

Context Clinical multiple endocrine neoplasia type 1 (MEN-1) is diagnosed by the presence
of at least 2 MEN-1–associated tumors. Many patients with acromegaly and clinical MEN-1 …

Transsphenoidal surgery is the first-line treatment for acromegaly. However, several factors
can modify surgical remission rates, such as the initial hormone levels, the size and …

Objective The results of previous studies on sex differences in mortality and comorbidities
among patients with acromegaly are diverse. We assessed sex differences in mortality and …

Background and objective Management of recurrent acromegaly is challenging for both
neurosurgeons and endocrinologists. Several treatment options including repeat surgery …